EGEIRO Pharma declares bankruptcy after decision of the Board of Directors

On March 7, 2025, biopharmaceutical company EGEIRO Pharma, formerly Theravet, announced its decision to declare bankruptcy. This decision was taken at a Board of Directors meeting in Gosselies, Belgium. Despite efforts to restructure the business and reduce debt since October 2024, the reclassification of a financial transaction as a reverse acquisition by Euronext has put an end to hopes of recovery.

The association with creditors and an investor allowed the company to reduce its debt by 719,000 euros. However, the suspension of EGEIRO shares and the inability to conclude a financial agreement led to this admission of bankruptcy. The Board of Directors thanks the stakeholders, in particular IRIS Capital Investissement, for their support in this difficult context.